Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 115 | 2024 | 12293 | 5.650 |
Why?
|
Hypoglycemic Agents | 53 | 2024 | 3150 | 2.520 |
Why?
|
Diabetes Mellitus | 24 | 2024 | 5889 | 2.140 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 17 | 2024 | 334 | 2.090 |
Why?
|
Hyperglycemia | 11 | 2022 | 1380 | 1.910 |
Why?
|
Blood Glucose | 33 | 2024 | 6381 | 1.870 |
Why?
|
Metformin | 14 | 2024 | 912 | 1.820 |
Why?
|
Sulfonylurea Compounds | 11 | 2024 | 221 | 1.760 |
Why?
|
Hypoglycemia | 8 | 2023 | 888 | 1.750 |
Why?
|
Food Supply | 6 | 2020 | 542 | 1.520 |
Why?
|
Dietary Services | 2 | 2020 | 17 | 1.350 |
Why?
|
Diabetes Complications | 8 | 2022 | 1341 | 1.060 |
Why?
|
Insulin | 19 | 2023 | 6597 | 0.950 |
Why?
|
Cardiovascular Diseases | 25 | 2024 | 15757 | 0.880 |
Why?
|
Gout | 6 | 2024 | 620 | 0.830 |
Why?
|
Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2022 | 30 | 0.800 |
Why?
|
Primary Health Care | 12 | 2021 | 4647 | 0.790 |
Why?
|
Life Style | 12 | 2024 | 3896 | 0.780 |
Why?
|
Glucosides | 6 | 2024 | 533 | 0.770 |
Why?
|
Diabetes, Gestational | 4 | 2018 | 1242 | 0.740 |
Why?
|
Acidosis, Lactic | 1 | 2022 | 145 | 0.730 |
Why?
|
Inpatients | 8 | 2024 | 2581 | 0.730 |
Why?
|
Drug Therapy, Computer-Assisted | 2 | 2012 | 198 | 0.670 |
Why?
|
Confusion | 2 | 2018 | 279 | 0.670 |
Why?
|
Health Behavior | 7 | 2021 | 2622 | 0.640 |
Why?
|
Weight Loss | 9 | 2023 | 2686 | 0.640 |
Why?
|
Obesity | 13 | 2024 | 12922 | 0.630 |
Why?
|
Benzhydryl Compounds | 5 | 2024 | 941 | 0.600 |
Why?
|
Insulinoma | 1 | 2018 | 121 | 0.590 |
Why?
|
Diet Therapy | 1 | 2018 | 151 | 0.570 |
Why?
|
Patient Care Team | 3 | 2018 | 2511 | 0.560 |
Why?
|
Albuminuria | 4 | 2023 | 659 | 0.560 |
Why?
|
Humans | 168 | 2024 | 760621 | 0.520 |
Why?
|
Food | 2 | 2018 | 771 | 0.510 |
Why?
|
Middle Aged | 74 | 2024 | 220352 | 0.480 |
Why?
|
Aged | 73 | 2024 | 169152 | 0.480 |
Why?
|
Pregnancy in Diabetics | 2 | 2015 | 194 | 0.470 |
Why?
|
Psychotherapy, Group | 1 | 2018 | 410 | 0.470 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2024 | 3455 | 0.460 |
Why?
|
Renal Insufficiency, Chronic | 8 | 2024 | 2290 | 0.460 |
Why?
|
Female | 99 | 2024 | 391270 | 0.440 |
Why?
|
Patient Compliance | 5 | 2018 | 2688 | 0.440 |
Why?
|
Male | 91 | 2024 | 359744 | 0.430 |
Why?
|
Kidney Diseases | 2 | 2023 | 2093 | 0.430 |
Why?
|
Insulin, Long-Acting | 2 | 2013 | 58 | 0.420 |
Why?
|
Nephrolithiasis | 2 | 2024 | 114 | 0.420 |
Why?
|
Risk Reduction Behavior | 2 | 2018 | 1109 | 0.400 |
Why?
|
Interdisciplinary Communication | 1 | 2018 | 934 | 0.400 |
Why?
|
Cohort Studies | 31 | 2024 | 41335 | 0.390 |
Why?
|
Hyperkalemia | 2 | 2024 | 231 | 0.390 |
Why?
|
Pharmacists | 2 | 2024 | 259 | 0.390 |
Why?
|
United States | 39 | 2024 | 72461 | 0.370 |
Why?
|
Self Care | 6 | 2020 | 793 | 0.370 |
Why?
|
Poverty | 5 | 2021 | 2695 | 0.370 |
Why?
|
Models, Psychological | 1 | 2015 | 827 | 0.370 |
Why?
|
Infarction | 1 | 2012 | 248 | 0.360 |
Why?
|
Insulin Infusion Systems | 1 | 2012 | 217 | 0.350 |
Why?
|
Nutrition Surveys | 4 | 2019 | 1725 | 0.340 |
Why?
|
Adult | 61 | 2024 | 219994 | 0.330 |
Why?
|
Behavior Therapy | 1 | 2015 | 868 | 0.330 |
Why?
|
Automation | 1 | 2012 | 580 | 0.330 |
Why?
|
Hypertension | 7 | 2022 | 8594 | 0.330 |
Why?
|
Patient Satisfaction | 3 | 2018 | 3448 | 0.320 |
Why?
|
Glucose | 12 | 2024 | 4351 | 0.320 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 2 | 2018 | 26 | 0.320 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 253 | 0.320 |
Why?
|
Body Mass Index | 11 | 2024 | 12914 | 0.320 |
Why?
|
Blood Glucose Self-Monitoring | 5 | 2024 | 457 | 0.300 |
Why?
|
Diabetic Angiopathies | 4 | 2020 | 822 | 0.300 |
Why?
|
Placenta | 3 | 2015 | 1702 | 0.290 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2010 | 412 | 0.290 |
Why?
|
Body Weight | 2 | 2020 | 4611 | 0.290 |
Why?
|
Heart Failure | 16 | 2024 | 11847 | 0.290 |
Why?
|
Patient-Centered Care | 2 | 2016 | 1416 | 0.290 |
Why?
|
Comparative Effectiveness Research | 6 | 2024 | 718 | 0.270 |
Why?
|
Quality of Life | 5 | 2022 | 13308 | 0.260 |
Why?
|
Myocardial Infarction | 7 | 2024 | 11891 | 0.260 |
Why?
|
Emigrants and Immigrants | 2 | 2023 | 539 | 0.260 |
Why?
|
Depression | 6 | 2024 | 8044 | 0.250 |
Why?
|
Cause of Death | 3 | 2024 | 3725 | 0.250 |
Why?
|
Developing Countries | 4 | 2021 | 2868 | 0.250 |
Why?
|
Clinical Trials as Topic | 2 | 2012 | 8056 | 0.240 |
Why?
|
Diabetic Retinopathy | 1 | 2013 | 1268 | 0.230 |
Why?
|
Monitoring, Physiologic | 1 | 2012 | 1784 | 0.230 |
Why?
|
Coronary Disease | 2 | 2017 | 5990 | 0.230 |
Why?
|
Medication Adherence | 4 | 2022 | 2165 | 0.220 |
Why?
|
Uric Acid | 3 | 2024 | 806 | 0.220 |
Why?
|
Respiratory Aspiration | 1 | 2024 | 89 | 0.220 |
Why?
|
Patient Education as Topic | 4 | 2024 | 2315 | 0.220 |
Why?
|
Cross-Over Studies | 2 | 2020 | 2061 | 0.220 |
Why?
|
Socioeconomic Factors | 7 | 2023 | 7806 | 0.210 |
Why?
|
Nutrition Therapy | 1 | 2024 | 102 | 0.210 |
Why?
|
Diabetic Ketoacidosis | 2 | 2023 | 257 | 0.210 |
Why?
|
Biomedical Research | 1 | 2018 | 3426 | 0.210 |
Why?
|
Quality of Health Care | 1 | 2018 | 4360 | 0.210 |
Why?
|
Blood Pressure | 4 | 2013 | 8525 | 0.210 |
Why?
|
Qualitative Research | 4 | 2024 | 2963 | 0.200 |
Why?
|
Cross-Sectional Studies | 16 | 2023 | 25942 | 0.200 |
Why?
|
Placenta Diseases | 2 | 2015 | 196 | 0.190 |
Why?
|
Patient Selection | 2 | 2024 | 4283 | 0.190 |
Why?
|
Drug Therapy, Combination | 7 | 2024 | 6498 | 0.190 |
Why?
|
Medicare | 13 | 2024 | 6786 | 0.190 |
Why?
|
Health Status | 2 | 2012 | 4081 | 0.190 |
Why?
|
Health Status Indicators | 1 | 2006 | 968 | 0.180 |
Why?
|
Cost-Benefit Analysis | 6 | 2018 | 5508 | 0.180 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5351 | 0.180 |
Why?
|
Sodium | 5 | 2024 | 1594 | 0.180 |
Why?
|
Hospitalization | 8 | 2024 | 10790 | 0.180 |
Why?
|
Pharmacoepidemiology | 1 | 2023 | 350 | 0.170 |
Why?
|
Fractures, Bone | 2 | 2023 | 2041 | 0.170 |
Why?
|
Educational Status | 2 | 2020 | 2515 | 0.170 |
Why?
|
Treatment Outcome | 16 | 2024 | 65017 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2021 | 3959 | 0.170 |
Why?
|
Patient Readmission | 3 | 2017 | 3323 | 0.160 |
Why?
|
Mexico | 4 | 2022 | 760 | 0.160 |
Why?
|
Glomerular Filtration Rate | 4 | 2023 | 2180 | 0.160 |
Why?
|
Remote Consultation | 1 | 2021 | 234 | 0.160 |
Why?
|
Health Services for the Aged | 1 | 2001 | 259 | 0.160 |
Why?
|
Algorithms | 5 | 2021 | 13981 | 0.160 |
Why?
|
Pharmacogenetics | 2 | 2015 | 680 | 0.160 |
Why?
|
Psychotherapy | 3 | 2018 | 1640 | 0.150 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2024 | 867 | 0.150 |
Why?
|
Goals | 1 | 2023 | 708 | 0.150 |
Why?
|
Patient Acceptance of Health Care | 3 | 2024 | 3164 | 0.150 |
Why?
|
Medical Records | 3 | 2012 | 1407 | 0.150 |
Why?
|
Mental Health | 1 | 2012 | 3213 | 0.150 |
Why?
|
Stroke | 4 | 2024 | 9962 | 0.150 |
Why?
|
Atherosclerosis | 2 | 2024 | 3517 | 0.140 |
Why?
|
Inflammation Mediators | 1 | 2005 | 1881 | 0.140 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39261 | 0.140 |
Why?
|
Urinary Tract Infections | 1 | 2023 | 814 | 0.140 |
Why?
|
Spouses | 1 | 2018 | 279 | 0.130 |
Why?
|
Feeding Behavior | 3 | 2018 | 3185 | 0.130 |
Why?
|
Risk Factors | 17 | 2024 | 74359 | 0.130 |
Why?
|
Glycemic Index | 2 | 2020 | 396 | 0.130 |
Why?
|
Focus Groups | 2 | 2021 | 1378 | 0.130 |
Why?
|
Comorbidity | 6 | 2020 | 10551 | 0.130 |
Why?
|
Diet, Carbohydrate-Restricted | 1 | 2018 | 261 | 0.130 |
Why?
|
Prevalence | 9 | 2021 | 15687 | 0.130 |
Why?
|
Geography | 1 | 2018 | 661 | 0.130 |
Why?
|
Triglycerides | 1 | 2023 | 2476 | 0.130 |
Why?
|
Hyperinsulinism | 1 | 2018 | 402 | 0.120 |
Why?
|
Health Facilities | 1 | 2020 | 578 | 0.120 |
Why?
|
Glipizide | 1 | 2015 | 48 | 0.120 |
Why?
|
Hospital Costs | 1 | 2001 | 976 | 0.120 |
Why?
|
Radiography, Abdominal | 1 | 2018 | 532 | 0.120 |
Why?
|
Exercise | 5 | 2020 | 5787 | 0.120 |
Why?
|
Public Assistance | 1 | 2015 | 47 | 0.120 |
Why?
|
Massachusetts | 3 | 2020 | 8803 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2022 | 21025 | 0.120 |
Why?
|
Genetic Variation | 1 | 2010 | 6551 | 0.120 |
Why?
|
Bariatric Surgery | 1 | 2024 | 1005 | 0.120 |
Why?
|
Academic Medical Centers | 2 | 2016 | 2754 | 0.110 |
Why?
|
Retrospective Studies | 13 | 2024 | 80372 | 0.110 |
Why?
|
Diabetes Insipidus, Neurogenic | 1 | 2013 | 20 | 0.110 |
Why?
|
Dysthymic Disorder | 1 | 2013 | 75 | 0.110 |
Why?
|
Inservice Training | 1 | 2016 | 375 | 0.110 |
Why?
|
Polyuria | 1 | 2013 | 37 | 0.110 |
Why?
|
Erythropoietin | 4 | 2002 | 720 | 0.110 |
Why?
|
Insulin-Secreting Cells | 1 | 2021 | 907 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 2448 | 0.110 |
Why?
|
Early Diagnosis | 1 | 2018 | 1180 | 0.110 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2024 | 366 | 0.110 |
Why?
|
Physicians, Family | 2 | 2007 | 349 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2020 | 2435 | 0.110 |
Why?
|
National Health Programs | 1 | 1996 | 441 | 0.110 |
Why?
|
Health Services Accessibility | 2 | 2020 | 5397 | 0.110 |
Why?
|
Acute Kidney Injury | 2 | 2023 | 1941 | 0.100 |
Why?
|
Cystic Fibrosis | 1 | 2022 | 1274 | 0.100 |
Why?
|
Pregnancy | 5 | 2018 | 29749 | 0.100 |
Why?
|
Canada | 3 | 2024 | 2128 | 0.100 |
Why?
|
Sodium-Glucose Transporter 2 | 2 | 2024 | 98 | 0.100 |
Why?
|
Anemia | 4 | 2003 | 1511 | 0.100 |
Why?
|
Europe | 4 | 2020 | 3441 | 0.100 |
Why?
|
Recurrence | 1 | 2024 | 8482 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1677 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 926 | 0.100 |
Why?
|
Reference Values | 2 | 2010 | 4925 | 0.100 |
Why?
|
Glycosuria | 1 | 2011 | 44 | 0.100 |
Why?
|
Heart Diseases | 1 | 2005 | 2809 | 0.100 |
Why?
|
Propensity Score | 3 | 2024 | 1928 | 0.100 |
Why?
|
Social Support | 2 | 2018 | 2145 | 0.090 |
Why?
|
Income | 1 | 2020 | 1875 | 0.090 |
Why?
|
Kidney | 2 | 2024 | 7064 | 0.090 |
Why?
|
Prenatal Care | 1 | 2018 | 1129 | 0.090 |
Why?
|
Phenotype | 3 | 2022 | 16546 | 0.090 |
Why?
|
Dacarbazine | 1 | 2013 | 560 | 0.090 |
Why?
|
Haiti | 2 | 2023 | 549 | 0.090 |
Why?
|
Computer Systems | 1 | 2012 | 470 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2020 | 3736 | 0.090 |
Why?
|
Boston | 3 | 2017 | 9280 | 0.090 |
Why?
|
Telemedicine | 2 | 2024 | 3018 | 0.090 |
Why?
|
Housing | 1 | 2015 | 665 | 0.090 |
Why?
|
Forecasting | 1 | 2019 | 2932 | 0.090 |
Why?
|
Urban Health | 1 | 2012 | 533 | 0.080 |
Why?
|
Delivery of Health Care | 1 | 2007 | 5325 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 618 | 0.080 |
Why?
|
Length of Stay | 2 | 2013 | 6479 | 0.080 |
Why?
|
Program Evaluation | 1 | 2018 | 2493 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58995 | 0.080 |
Why?
|
Hospital Bed Capacity, 500 and over | 1 | 2008 | 114 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1500 | 0.080 |
Why?
|
Telephone | 2 | 2024 | 624 | 0.080 |
Why?
|
Pilot Projects | 3 | 2020 | 8555 | 0.080 |
Why?
|
Statistics as Topic | 1 | 2015 | 2362 | 0.080 |
Why?
|
Societies, Medical | 4 | 2020 | 3905 | 0.080 |
Why?
|
Depressive Disorder | 2 | 2013 | 3726 | 0.080 |
Why?
|
Veterans | 1 | 2021 | 2642 | 0.070 |
Why?
|
Disease Progression | 3 | 2023 | 13502 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6180 | 0.070 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2007 | 92 | 0.070 |
Why?
|
Hospitals, General | 1 | 2012 | 795 | 0.070 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2012 | 516 | 0.070 |
Why?
|
Efficiency, Organizational | 1 | 2012 | 697 | 0.070 |
Why?
|
Physician-Patient Relations | 3 | 2017 | 3242 | 0.070 |
Why?
|
Thiophenes | 1 | 2011 | 587 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3334 | 0.070 |
Why?
|
Attitude to Health | 1 | 2015 | 2029 | 0.070 |
Why?
|
Age of Onset | 1 | 2013 | 3301 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3392 | 0.070 |
Why?
|
Stress, Psychological | 3 | 2013 | 4446 | 0.070 |
Why?
|
Health Surveys | 3 | 2021 | 4063 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2018 | 14495 | 0.070 |
Why?
|
Critical Pathways | 1 | 2009 | 475 | 0.070 |
Why?
|
Eicosapentaenoic Acid | 1 | 2010 | 613 | 0.060 |
Why?
|
Computer Simulation | 1 | 2019 | 6218 | 0.060 |
Why?
|
Kidney Failure, Chronic | 3 | 2003 | 2471 | 0.060 |
Why?
|
Glucose Tolerance Test | 2 | 2021 | 1175 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3291 | 0.060 |
Why?
|
Triazoles | 2 | 2013 | 904 | 0.060 |
Why?
|
Consensus | 3 | 2019 | 3113 | 0.060 |
Why?
|
Sickness Impact Profile | 1 | 2006 | 298 | 0.060 |
Why?
|
Patient Discharge | 2 | 2012 | 3476 | 0.060 |
Why?
|
Probability | 1 | 2010 | 2475 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5075 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2932 | 0.060 |
Why?
|
Diet | 2 | 2015 | 8010 | 0.060 |
Why?
|
Family Practice | 1 | 2007 | 510 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2022 | 10344 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5209 | 0.060 |
Why?
|
History, 21st Century | 2 | 2020 | 1575 | 0.060 |
Why?
|
Odds Ratio | 3 | 2020 | 9716 | 0.060 |
Why?
|
Ferric Compounds | 2 | 2002 | 377 | 0.050 |
Why?
|
Referral and Consultation | 1 | 1996 | 3598 | 0.050 |
Why?
|
Docosahexaenoic Acids | 1 | 2010 | 912 | 0.050 |
Why?
|
Alleles | 2 | 2015 | 6898 | 0.050 |
Why?
|
Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
Depressive Disorder, Major | 2 | 2013 | 4744 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12965 | 0.050 |
Why?
|
Endothelium | 1 | 2005 | 764 | 0.050 |
Why?
|
Electronic Mail | 1 | 2024 | 213 | 0.050 |
Why?
|
Diabetic Nephropathies | 1 | 2010 | 988 | 0.050 |
Why?
|
Mycoses | 1 | 2006 | 387 | 0.050 |
Why?
|
Age Factors | 2 | 2012 | 18416 | 0.050 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 91 | 0.050 |
Why?
|
Iron | 2 | 2001 | 1786 | 0.050 |
Why?
|
Mortality | 2 | 2024 | 2916 | 0.050 |
Why?
|
Specialization | 1 | 2007 | 778 | 0.050 |
Why?
|
Dyslipidemias | 2 | 2022 | 895 | 0.050 |
Why?
|
Thrombosis | 1 | 2015 | 3052 | 0.050 |
Why?
|
Social Class | 2 | 2021 | 2005 | 0.050 |
Why?
|
Pregnancy Outcome | 1 | 2012 | 2907 | 0.050 |
Why?
|
Matched-Pair Analysis | 1 | 2021 | 284 | 0.050 |
Why?
|
Connecticut | 1 | 2001 | 365 | 0.050 |
Why?
|
Antifungal Agents | 1 | 2006 | 749 | 0.050 |
Why?
|
Self Report | 1 | 2012 | 3711 | 0.050 |
Why?
|
Neutropenia | 1 | 2006 | 884 | 0.040 |
Why?
|
Medicaid | 1 | 2014 | 2815 | 0.040 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2010 | 1387 | 0.040 |
Why?
|
Diet, Fat-Restricted | 1 | 2023 | 330 | 0.040 |
Why?
|
Azetidines | 1 | 2001 | 141 | 0.040 |
Why?
|
Hypolipidemic Agents | 1 | 2005 | 626 | 0.040 |
Why?
|
Adolescent | 9 | 2024 | 87810 | 0.040 |
Why?
|
Mental Disorders | 1 | 2020 | 6796 | 0.040 |
Why?
|
Adiponectin | 1 | 2006 | 1115 | 0.040 |
Why?
|
Evidence-Based Medicine | 1 | 2012 | 3696 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2020 | 10827 | 0.040 |
Why?
|
C-Peptide | 1 | 2021 | 433 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3388 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29658 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 422 | 0.040 |
Why?
|
Diabetic Neuropathies | 1 | 2022 | 406 | 0.040 |
Why?
|
Medicine | 1 | 2007 | 943 | 0.040 |
Why?
|
Cholesterol | 2 | 2021 | 2924 | 0.040 |
Why?
|
Glucagon-Like Peptides | 1 | 2020 | 159 | 0.040 |
Why?
|
Bangladesh | 1 | 2020 | 728 | 0.040 |
Why?
|
Microvessels | 1 | 2022 | 572 | 0.040 |
Why?
|
Fever | 1 | 2006 | 1617 | 0.040 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2020 | 280 | 0.040 |
Why?
|
Incidence | 3 | 2024 | 21392 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 877 | 0.040 |
Why?
|
Prospective Studies | 3 | 2018 | 54303 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 816 | 0.040 |
Why?
|
Models, Economic | 1 | 2001 | 719 | 0.040 |
Why?
|
Atrophy | 1 | 2022 | 1627 | 0.040 |
Why?
|
Acute Disease | 1 | 2007 | 7269 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2014 | 4775 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 783 | 0.030 |
Why?
|
Risk Assessment | 4 | 2021 | 24123 | 0.030 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2000 | 368 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2015 | 6659 | 0.030 |
Why?
|
Placental Circulation | 1 | 2015 | 37 | 0.030 |
Why?
|
Injections, Subcutaneous | 3 | 2002 | 680 | 0.030 |
Why?
|
Adiposity | 1 | 2005 | 1858 | 0.030 |
Why?
|
Government | 1 | 1996 | 160 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 12531 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2005 | 2061 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20509 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 36290 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2015 | 6238 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20080 | 0.030 |
Why?
|
Injections, Intravenous | 3 | 2002 | 1385 | 0.030 |
Why?
|
Transcription Factor 7-Like 2 Protein | 1 | 2015 | 152 | 0.030 |
Why?
|
Young Adult | 6 | 2021 | 58741 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2005 | 2629 | 0.030 |
Why?
|
Sample Size | 1 | 2017 | 840 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2001 | 1155 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22053 | 0.030 |
Why?
|
Anticholesteremic Agents | 1 | 2001 | 987 | 0.030 |
Why?
|
Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2015 | 507 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2024 | 2283 | 0.030 |
Why?
|
Obesity, Morbid | 1 | 2024 | 1287 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2013 | 7818 | 0.030 |
Why?
|
Gender Identity | 1 | 2018 | 698 | 0.030 |
Why?
|
Disease Management | 1 | 2024 | 2514 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12159 | 0.030 |
Why?
|
Hospitals, Teaching | 1 | 2017 | 1166 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1931 | 0.030 |
Why?
|
Patient Preference | 1 | 2020 | 922 | 0.030 |
Why?
|
Glucaric Acid | 2 | 2002 | 9 | 0.030 |
Why?
|
Logistic Models | 2 | 2020 | 13314 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2001 | 2420 | 0.020 |
Why?
|
Health Priorities | 1 | 2015 | 374 | 0.020 |
Why?
|
Health Care Costs | 1 | 2024 | 3258 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2020 | 3735 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7475 | 0.020 |
Why?
|
California | 1 | 2015 | 1416 | 0.020 |
Why?
|
Pituitary Gland | 1 | 2013 | 637 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4354 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2013 | 998 | 0.020 |
Why?
|
Health Promotion | 1 | 2021 | 2206 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2622 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2017 | 878 | 0.020 |
Why?
|
Severity of Illness Index | 4 | 2012 | 15840 | 0.020 |
Why?
|
Astrocytoma | 1 | 2013 | 775 | 0.020 |
Why?
|
Needs Assessment | 1 | 2015 | 1139 | 0.020 |
Why?
|
Pyrazines | 1 | 2013 | 1199 | 0.020 |
Why?
|
Hyperlipidemias | 1 | 2012 | 782 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6360 | 0.020 |
Why?
|
Registries | 1 | 2022 | 8469 | 0.020 |
Why?
|
Counseling | 1 | 2013 | 1548 | 0.020 |
Why?
|
Physicians, Primary Care | 1 | 2012 | 624 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2016 | 5201 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2001 | 15289 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 4899 | 0.010 |
Why?
|
Dietary Carbohydrates | 1 | 2008 | 892 | 0.010 |
Why?
|
Thiazolidinediones | 1 | 2007 | 465 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 2009 | 820 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2017 | 12427 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8651 | 0.010 |
Why?
|
Stroke Volume | 3 | 2002 | 5523 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8624 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14660 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2002 | 6538 | 0.010 |
Why?
|
Choice Behavior | 1 | 2007 | 821 | 0.010 |
Why?
|
Dietary Fats | 1 | 2008 | 1992 | 0.010 |
Why?
|
Sucrose | 1 | 2001 | 156 | 0.010 |
Why?
|
Vulva | 1 | 1959 | 82 | 0.010 |
Why?
|
Administration, Oral | 1 | 2007 | 4035 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2012 | 3865 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2006 | 2693 | 0.010 |
Why?
|
Chromatography, Liquid | 1 | 2001 | 987 | 0.010 |
Why?
|
Perineum | 1 | 1959 | 208 | 0.010 |
Why?
|
Vagina | 2 | 1963 | 837 | 0.010 |
Why?
|
Syndrome | 1 | 2003 | 3280 | 0.010 |
Why?
|
Oxygen Consumption | 1 | 2002 | 1843 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 2628 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2006 | 6828 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 15789 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2001 | 2192 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2006 | 3839 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17790 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2013 | 8986 | 0.010 |
Why?
|
Linear Models | 1 | 2001 | 5877 | 0.010 |
Why?
|
Cytokines | 1 | 2006 | 7343 | 0.010 |
Why?
|
Sensory Deprivation | 2 | 1963 | 106 | 0.010 |
Why?
|
Hemorrhage | 1 | 1959 | 3600 | 0.000 |
Why?
|
Authoritarianism | 1 | 1964 | 11 | 0.000 |
Why?
|
Psychological Tests | 1 | 1964 | 639 | 0.000 |
Why?
|
Ovulation | 1 | 1963 | 181 | 0.000 |
Why?
|
Education | 1 | 1964 | 534 | 0.000 |
Why?
|
Imagination | 1 | 1963 | 226 | 0.000 |
Why?
|
Religion | 1 | 1964 | 376 | 0.000 |
Why?
|
Vision, Ocular | 1 | 1963 | 454 | 0.000 |
Why?
|
Attitude | 1 | 1964 | 777 | 0.000 |
Why?
|
Cervix Uteri | 1 | 1963 | 582 | 0.000 |
Why?
|
Deafness | 1 | 1963 | 457 | 0.000 |
Why?
|
Ethiodized Oil | 1 | 1958 | 25 | 0.000 |
Why?
|
Hysterosalpingography | 1 | 1958 | 26 | 0.000 |
Why?
|
Interpersonal Relations | 1 | 1964 | 1428 | 0.000 |
Why?
|
Sensation | 1 | 1958 | 331 | 0.000 |
Why?
|
Alcoholism | 1 | 1964 | 1961 | 0.000 |
Why?
|
Contrast Media | 1 | 1958 | 5305 | 0.000 |
Why?
|